Sitravatinib is primarily used in cancer research and development, particularly as an investigational tyrosine kinase inhibitor. It targets a broad range of receptor tyrosine kinases, including those involved in tumor growth and immune evasion, such as MET, AXL, RET, and members of the TAM family. This makes it a promising candidate for overcoming resistance to existing therapies in solid tumors. It has shown potential in combination with immune checkpoint inhibitors, enhancing anti-tumor immune responses by modulating the tumor microenvironment. Studies are exploring its efficacy in non-small cell lung cancer, melanoma, and other advanced solid tumors. Due to its dual action on both cancer cells and immune suppression pathways, sitravatinib is being evaluated in clinical trials to improve patient response rates and prolong progression-free survival.